Anti-HIV gel shows promise in large-scale study in women

An investigational vaginal gel intended to prevent HIV infection in women has demonstrated encouraging signs of success in a clinical trial conducted in Africa and the United States. Findings of the recently concluded study, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, were presented today at the Conference on Retroviruses and Opportunistic Infections in Montreal.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news153399286.html">Anti-HIV gel shows promise in large-scale study in women</a></p> <p>An investigational vaginal gel intended to prevent HIV infection in women has demonstrated encouraging signs of success in a clinical trial conducted in Africa and the United States. Findings of the recently concluded study, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, were presented today at the Conference on Retroviruses and Opportunistic Infections in Montreal.</p>